PetMed Express, Inc. filings document the regulatory record for a Florida public company operating the PetMeds and PetCareRx pet pharmacy businesses. Annual and current reports disclose operating results, non-GAAP reconciliations, intangible-asset impairment matters involving the PCRX trade name, and the financial reporting issues reflected in Forms 12b-25 and Nasdaq continued-listing notices.
Other filings cover governance and capital-structure matters, including annual meeting voting results, director elections, executive compensation advisory votes, audit committee composition, amendments to the shareholder rights agreement, and modifications to security holder rights. The record also includes Form 8-K disclosures for material agreements, board appointments, results releases, and listing compliance communications.
PetMed Express reported receiving a Nasdaq notice on November 12, 2025 for failing to timely file its Quarterly Reports on Form 10‑Q for the periods ended June 30, 2025 (Q1) and September 30, 2025 (Q2), in addition to a prior delinquent Form 10‑K for the year ended March 31, 2025. The notice requires an updated compliance plan by November 28, 2025, and states any staff exception, if granted, will be limited to a maximum of 180 days from the initial delinquency, or December 29, 2025.
The company said the notice has no immediate effect on its Nasdaq listing and it intends to complete and file the Q1 10‑Q and Q2 10‑Q as promptly as possible. Separately, PetMed furnished a press release announcing preliminary, unaudited estimated revenues for the three‑ and nine‑month periods ended September 30, 2025; that information was furnished, not filed, under Item 2.02.
PetMed Express (PETS) filed a Form 12b-25, notifying a late filing of its Form 10-Q for the quarter ended September 30, 2025, as it first needs to complete the delayed June 30, 2025 Form 10-Q following a now-completed Audit Committee investigation.
For the September quarter, net sales are estimated at $43.4–$44.5 million, compared with $58.0 million in the prior-year period. For the six months ended September 30, 2025, net sales are expected at $94.5–$95.6 million, versus $124.3 million a year earlier. The company is analyzing the timing and amount of an anticipated goodwill impairment and cannot currently estimate operating or net income for these periods.
PetMed Express (PETS) reported that its CAO and Interim CFO acquired 20,000 shares of restricted stock on October 30, 2025 at $0, as disclosed on a Form 4.
The award vests as to 50% of the granted shares on October 30, 2026 and 50% on October 30, 2027, subject to continued employment through each vesting date. Following this grant, the officer beneficially owns 70,000 shares.
PetMed Express (PETS) reported a director’s acquisition of 34,866 shares of restricted common stock on 10/30/2025 at $0, as disclosed in a Form 4. Following the award, the director beneficially owns 34,866 shares, held directly. The grant was made under the company’s 2024 Omnibus Incentive Plan and is scheduled to vest in two tranches: 1,020 shares on 10/19/2026 and 33,846 shares on 10/30/2026, each vesting subject to continued service on the Board of Directors.
PetMed Express (PETS) reported a director equity grant. The reporting person acquired 33,846 shares of common stock as a restricted stock award at $0 on October 30, 2025, issued under the company’s 2024 Omnibus Incentive Plan. The award vests as to all granted shares on October 30, 2026, subject to continued service on the Board of Directors. After this transaction, the reporting person beneficially owned 42,719 shares, held directly.
PetMed Express (PETS) director Leah A. Solivan reported an award of 33,846 shares of common stock on 10/30/2025 at $0 (Form 4, code A), granted as restricted stock under the company’s 2024 Omnibus Incentive Plan.
The award vests on October 30, 2026, subject to continued service on the Board of Directors. Following this grant, Solivan’s beneficial ownership is 42,289 shares, held directly.
PetMed Express (PETS) reported a director equity grant on a Form 4. On 10/30/2025, the director acquired 33,846 shares of common stock as a restricted stock award at a reported price of $0, under the company’s 2024 Omnibus Incentive Plan. Following the grant, the director beneficially owned 36,373 shares, held directly.
The award vests in full on October 30, 2026, subject to continued service on the Board of Directors.
PetMed Express (PETS) reported an initial insider ownership filing. Director James LaCamp filed a Form 3 with an event date of 10/19/2025, stating no securities are beneficially owned.
The filing was made by one reporting person and reflects his status as a director of the company.
PetMed Express (PETS) announced board and leadership updates. The Board appointed James LaCamp as a director effective immediately and named him to the Audit Committee and the Compensation and Human Capital Committee. He will become Audit Committee Chair on October 30, 2025 and is designated an SEC “audit committee financial expert.”
The Board also approved an Interim Executive Employment Agreement with Leslie C.G. Campbell to serve as Interim CEO and President for a one-year term from August 11, 2025 through August 10, 2026. The role is at-will and may be terminated by either party without severance. Compensation includes a $1.3 million annual base salary, four weeks of vacation, customary expense reimbursement, and standard employee benefits, with full-time, in-person work at the Delray Beach headquarters. The agreement includes confidentiality, non-solicitation, and a one-year post-employment non-compete. The company furnished the agreement as Exhibit 10.1 and a related press release as Exhibit 99.1.
PetMed Express (PETS) furnished an Item 2.02 update announcing it issued a press release with preliminary, unaudited financial results for the fiscal year ended March 31, 2025, and other financial information. The press release is included as Exhibit 99.1 and incorporates non-GAAP measures with reconciliations. The company highlights forward-looking statements, including expectations regarding the timing of its Form 10-K filing. The materials are furnished, not filed, under the Exchange Act.